Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells

References

• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF et al., Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371(16):1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• Maher J. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012; 2012:278093; PMID:23304553; http://dx.doi.org/10.5402/2012/278093
   PubMedGoogle Scholar
• Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, Purdon T, Pegram HJ, Brentjens RJ. Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression. Mol Ther 2015; 23(4):769-78; PMID:25582824; http://dx.doi.org/10.1038/mt.2015.4
   PubMed Web of Science ®Google Scholar
• Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 2013; 6:47; PMID:23829929; PMID:24353912; http://dx.doi.org/10.1186/1756-8722-6-47
   PubMed Web of Science ®Google Scholar
• John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2013; 2(10):e26286; PMID:24353912; http://dx.doi.org/10.4161/onci.26286
   PubMed Web of Science ®Google Scholar
• Heise C, Carter T, Schafer P, Chopra R. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther 2010; 10 (10):1663-72; PMID:20942636; http://dx.doi.org/10.1586/era.10.135
   PubMed Web of Science ®Google Scholar
• Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X et al., Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343(6168): 301-5; PMID:24292625; http://dx.doi.org/10.1126/science.1244851
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A et al., Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol 2014; 164(6):811-21; PMID:24328678; http://dx.doi.org/10.1111/bjh.12708
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG et al., Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103(5):1787-90; PMID:14512311; http://dx.doi.org/10.1182/blood-2003-02-0361
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, Wolbring G, Govinda S, Corral LG, Payvandi F et al., Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003; 305(3):1222-32; PMID:12649301; http://dx.doi.org/10.1124/jpet.102.048496
   PubMed Web of Science ®Google Scholar
• Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187(11):1885-92; PMID:9607928; http://dx.doi.org/10.1084/jem.187.11.1885
   PubMed Web of Science ®Google Scholar
• Klanova M, Soukup T, Jaksa R, Molinsky J, Lateckova L, Maswabi BC, Prukova D, Brezinova J, Michalova K, Vockova P et al., Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Lab Invest 2014; 94(7):806-17; PMID:24862967; http://dx.doi.org/10.1038/labinvest.2014.61
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD et al., Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67(2):746-55; PMID:17234786; http://dx.doi.org/10.1158/0008-5472.CAN-06-2317
   PubMed Web of Science ®Google Scholar
• Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT et al., Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010; 116 (17):3227-37; PMID:20651070; http://dx.doi.org/10.1182/blood-2010-04-279893
   PubMed Web of Science ®Google Scholar
• Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG et al., Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22(10):1925-32; PMID:18596740; http://dx.doi.org/10.1038/leu.2008.174
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118(7):2427-37; PMID:18551193
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012; 120 (7):1412-21; PMID:22547582; http://dx.doi.org/10.1182/blood-2012-02-411678
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58(7):1033-45; PMID:19009291; http://dx.doi.org/10.1007/s00262-008-0620-4
   PubMed Web of Science ®Google Scholar
• Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB et al., Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.Blood 2011; 118(9):2413-9; PMID:21690556; http://dx.doi.org/10.1182/blood-2011-04-348292
   PubMed Web of Science ®Google Scholar
• Sakamaki I, Kwak LW, Cha SC, Yi Q, Lerman B, Chen J, Surapaneni S, Bateman S, Qin H. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 2014; 28(2):329-37; PMID:23765229; http://dx.doi.org/10.1038/leu.2013.177
   PubMed Web of Science ®Google Scholar
• Haslett PA, Hanekom WA, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003; 187 (6):946-55; PMID:12660941; http://dx.doi.org/10.1086/368126
   PubMed Web of Science ®Google Scholar
• Franklin RA, Tordai A, Patel H, Gardner AM, Johnson GL, Gelfand EW. Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. J Clin Invest 1994; 93(5):2134-40; PMID:8182145; http://dx.doi.org/10.1172/JCI117209
   PubMed Web of Science ®Google Scholar
• Marchingo JM, Kan A, Sutherland RM, Duffy KR, Wellard CJ, Belz GT, Lew AM, Dowling MR, Heinzel S, Hodgkin PD. T cell signaling. Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion. Science 2014; 346(6213):1123-7; PMID:25430770; http://dx.doi.org/10.1126/science.1260044
   PubMed Web of Science ®Google Scholar
• Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y et al., CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012; 119(17):3940-50; PMID:22308288; http://dx.doi.org/10.1182/blood-2011-10-387969
   PubMed Web of Science ®Google Scholar
• Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 2013; 6:47; PMID:23829929; http://dx.doi.org/10.1186/1756-8722-6-47
   PubMed Web of Science ®Google Scholar